<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955537</url>
  </required_header>
  <id_info>
    <org_study_id>1R01HL127215-01A1</org_study_id>
    <secondary_id>HUM00114202</secondary_id>
    <nct_id>NCT02955537</nct_id>
  </id_info>
  <brief_title>MI-BP: mHealth to Improve Blood Pressure Control</brief_title>
  <acronym>MI-BP</acronym>
  <official_title>MI-BP: mHealth to Improve Blood Pressure Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate a multicomponent mobile intervention to change multiple&#xD;
      hypertension-related health behaviors in minorities and the underserved with uncontrolled&#xD;
      hypertension. Half of the participants will receive a mobile intervention designed to improve&#xD;
      physical activity, sodium intake, and medication adherence. The other half will receive usual&#xD;
      care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2018</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean systolic blood pressure</measure>
    <time_frame>from baseline to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in physical activity as measured by the International Physical Activity Questionnaire (IPAQ-SF)</measure>
    <time_frame>from baseline to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sodium intake as measured by the Block Sodium Screener</measure>
    <time_frame>from baseline to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in medication adherence as measured by Adherence to Refills and Medications Scale (ARMS)</measure>
    <time_frame>from baseline to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure control</measure>
    <time_frame>from baseline to 1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost-effectiveness of MI-BP compared to usual care</measure>
    <time_frame>within-trial</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cost-effectiveness of MI-BP compared to usual care</measure>
    <time_frame>long-term</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care participants will be given a prescription for antihypertensive medications, printed educational materials on hypertension, and a home blood pressure monitor for daily use, but will receive no further intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MI-BP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MI-BP participants will receive an antihypertensive medication prescription, and be asked to use technology-mediated devices/services linked to positive changes in target behavior/outcome including the MI-BP app, a secure, mHealth platform that will be installed on participant smartphones.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MI-BP</intervention_name>
    <description>MI-BP includes the following components: 1) Home blood pressure monitoring 2) Physical activity monitoring 3) Sodium intake self-monitoring 4) Physical activity and sodium intake goal setting 5) Educational messaging via push notification and in-app messaging 6) motivational messaging 7) tailored messaging relevant to individual participants and 8) medication reminders.</description>
    <arm_group_label>MI-BP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Detroit-area residents&#xD;
&#xD;
          -  Hypertensive&#xD;
&#xD;
          -  Owning a compatible smartphone&#xD;
&#xD;
          -  Presenting to the Detroit Medical Center Detroit Receiving, Sinai-Grace Hospital, or&#xD;
             selected Community Health Screening Events with, but not necessarily for, uncontrolled&#xD;
             blood pressure (systolic blood pressure â‰¥ 135 mm Hg at triage and on repeat&#xD;
             measurement using the BpTRU device).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No self-reported prior history of hypertension&#xD;
&#xD;
          -  No hypertension diagnosis documented in their medical record&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Presenting with an acute illness necessitating immediate medical intervention&#xD;
&#xD;
          -  Presenting with an admission to the hospital for critical reasons (as determined by&#xD;
             the attending physician)&#xD;
&#xD;
          -  Pregnant (as determined by a dip test at screening), or self-report during trial.&#xD;
&#xD;
          -  Having the following serious comorbidities or confounders due to the fact that they&#xD;
             may make blood pressure control difficult or necessitate frequent Emergency Department&#xD;
             use or hospitalization:&#xD;
&#xD;
               -  Previous diagnosis of resistant hypertension (or current use of 3 or more&#xD;
                  maximally dosed antihypertensive agents without achievement of blood pressure&#xD;
                  control)&#xD;
&#xD;
               -  Steroid dependent asthma or emphysema&#xD;
&#xD;
               -  Cirrhosis or hepatic failure&#xD;
&#xD;
               -  Chronic heart failure (any stage)&#xD;
&#xD;
               -  Previous diagnosis of acute myocardial infarction, angina (stable or unstable),&#xD;
                  or known coronary artery disease&#xD;
&#xD;
               -  Previous diagnosis of cerebrovascular disease (including transient ischemic&#xD;
                  attack or stroke)&#xD;
&#xD;
               -  Known valvular heart disease&#xD;
&#xD;
               -  Stage IV or V chronic kidney disease&#xD;
&#xD;
               -  Cancer (terminal or undergoing active chemotherapeutic or radiation therapy)&#xD;
&#xD;
          -  Patients with other serious medical conditions that may affect their ability to&#xD;
             self-monitor blood pressure (such a dementia)&#xD;
&#xD;
          -  Having a history of alcohol or drug abuse as determined by the CAGE-AID questionnaire&#xD;
             (excluded if 2 or more)&#xD;
&#xD;
          -  Week 2 measurement of systolic blood pressure &lt; 130 mm Hg using the BpTRU device or&#xD;
             study-issued BP cuff.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorraine R Buis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reema Kadri, MLIS</last_name>
    <phone>734-998-7120</phone>
    <phone_ext>312</phone_ext>
    <email>rkadri@med.umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katee Dawood</last_name>
    </contact>
    <investigator>
      <last_name>Phillip Levy, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Lorraine Buis</investigator_full_name>
    <investigator_title>Assistant Professor of Family Medicine, Medical School and Assistant Professor of Information, School of Information</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>mHealth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

